Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who have not received insulin, according to a study published online Sept. 10 in the New England Journal of Medicine to coincide with the annual meeting of the European Association for the Study of Diabetes, held from from Sept. 9 to 13 in Madrid.
Carol Wysham, M.D., from the MultiCare Rockwood Center for Diabetes and Endocrinology in Spokane, Washington, and colleagues conducted a 52-week, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned to receive efsitora (466 patients) or degludec (462 patients).
The researchers found that from baseline to week 52, there was a decrease in the mean glycated hemoglobin level from 8.21 to 6.97 percent with efsitora and from 8.24 to 7.05 percent with degludec (estimated treatment difference, 0.09 percentage points), with the results demonstrating noninferiority. In participants using and not using glucagon like peptide-1 receptor agonists, efsitora was noninferior to degludec with respect to change in the glycated hemoglobin level. The percentage of time that the glucose level was within target range was 64.3 and 61.2 percent with efsitora and degludec, respectively (estimated treatment difference, 3.1 percentage points). The rate of combined clinically significant or severe hypoglycemia was 0.58 and 0.45 events per participant-year of exposure with efsitora and degludec, respectively (estimated rate ratio, 1.30).
"Noninferiority to once-daily degludec with respect to the change in the glycated hemoglobin level from baseline to week 52 was shown," the authors write.
Several authors disclosed ties to the pharmaceutical industry, including Eli Lilly, which funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.